2023 (Gyo-Ke) 10019 [Method of Treating Atopic Dermatitis … by Administering an IL-4R Antagonist
Updated: 6 hours ago
Article information
Article type: Case note
Category: Patents
Topics: Inventive step, Support requirement
First published on this website: 2026-11-01
Display and classification checked: November 2, 2026
Originally published on Ameblo: 2024-11-28 (Japan time). Full English translation.
2023 (Gyo-Ke) 10019 [Method of Treating Atopic Dermatitis by Administering an IL-4R Antagonist] <Miyasaka>
The only difference from the primary reference (a clinical-trial protocol) is whether it is a medicine or an investigational drug.
⇒ The Phase 2 success rate for allergic diseases is 33%.
⇒ A person skilled in the art cannot be said to understand, without waiting for the trial results, that the investigational drug is necessarily therapeutically effective.
⇒ Inventive step: satisfied
*For medical-use patents, when to file during clinical trials requires consideration in relation to the support requirement. One would like to file early and claim priority in several stages, but clinical trials last more than a year, so this is always difficult.
“The pharmacological test results disclosed in the specification concern only mAb1…. However, …the mechanism is that mAb1 binds to IL-4R and blocks IL-4R signaling …; therefore, a person skilled in the art can understand that agents other than mAb1 … have the same functions and effects.”
⇒ Support requirement: satisfied
Translator’s notes (editorial)
The supplied title is truncated and lacks a closing bracket; retained. The full body heading is translated in full.
Related articles
Update history
The first-published date remains unchanged. Display maintenance, classification changes, related-article updates, and text corrections are recorded separately.
November 1, 2026: First published on this website.
November 2, 2026: Added article information, classification, topics, language navigation, related articles where the same case was confirmed, consultation guidance, and SEO. The original text and first-published date were preserved.
Comments